A randomized phase II study comparing preoperative mFOLFOX6 versus FOLFOXIRI for locally advanced colon cancer: JCOG2006

被引：0

作者：

Hashimoto, Tadayoshi ^{[1
]}

Maruyama, Satoshi ^{[2
]}

Takii, Yasumasa ^{[2
]}

Mizusawa, Junki ^{[1
]}

Kataoka, Tomoko ^{[1
]}

Fukuda, Haruhiko ^{[1
]}

Tsukamoto, Shunsuke ^{[3
]}

Takashima, Atsuo ^{[4
]}

Hamaguchi, Tetsuya ^{[5
]}

Kanemitsu, Yukihide ^{[3
]}

Colorectal Canc Study Grp, Colorectal Canc Study Grp

Japan Clinical Oncology Grp, Japan Clinical Oncology Grp

机构：

[1] Natl Canc Ctr, Japan Clin Oncol Grp, Operat Off, Data Ctr, Tokyo, Japan

[2] Niigata Canc Ctr Hosp, Dept Surg, Niigata, Japan

[3] Natl Canc Ctr, Dept Colorectal Surg, Tokyo, Japan

[4] Natl Canc Ctr, Dept Gastrointestinal Med Oncol, Tokyo, Japan

[5] Saitama Med Univ Int Med Ctr, Dept Gastroenterol Oncol, Hidaka, Japan

来源：

FUTURE ONCOLOGY | 2023年 / 19卷 / 28期

关键词：

colon cancer; FOLFOXIRI; locally advanced; mFOLFOX6; preoperative chemotherapy; selection design; METASTATIC COLORECTAL-CANCER; COMPUTED-TOMOGRAPHY; 1ST-LINE TREATMENT; FLEXIBLE DESIGN; RECTAL-CANCER; OPEN-LABEL; OXALIPLATIN; FOLFIRI; CLASSIFICATION; CHEMOTHERAPY;

D O I：

10.2217/fon-2023-0091

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The prognosis of locally advanced colon cancer (LACC) with surgical resection followed only by adjuvant chemotherapy is poor. Preoperative chemotherapy for LACC patients with risk factors such as cT4bN+ or cT3-4aN2-3 has attracted attention. Here, the authors describe the rationale and design of JCOG2006, a randomized phase II study comparing preoperative chemotherapy with mFOLFOX6 versus FOLFOXIRI for LACC. Their efficacy and safety are evaluated and a determination of which is the more promising treatment will be conducted in a subsequent phase III trial. A total of 86 patients will be accrued from 44 institutions over 2 years. The primary end point is the proportion of patients with a Tumor Regression Score of 0-2, and secondary end points include overall survival, response rate and adverse events.Clinical Trial Registration: jRCTs031210365 (https://jrct.niph.go.jp/) A randomized phase II selection design trial for resectable locally advanced colon cancer to determine whether mFOLFOX6 or FOLFOXIRI is more promising for a subsequent phase III trial.

引用

页码：1897 / 1904

页数：8

共 50 条

[21] Randomized phase II open-label study of mFOLFOX6 in combination with linifanib or bevacizumab for metastatic colorectal cancer
O'Neil, Bert H.
Cainap, Calin
Van Cutsem, Eric
Gorbunova, Vera A.
Karapetis, Christos Stelios
Berlin, Jordan
Goldberg, Richard M.
Qin, Qin
Qian, Jiang
Ricker, Justin L.
McKee, Mark D.
Carlson, Dawn M.
Kim, Tae Won
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[22] A Randomized Phase II/III Trial Comparing Hepatectomy Followed by mFOLFOX6 with Hepatectomy Alone as Treatment for Liver Metastasis from Colorectal Cancer: Japan Clinical Oncology Group Study JCOG0603
Kanemitsu, Yukihide
Kato, Tomoyuki
Shimizu, Yasuhiro
Inaba, Yoshitaka
Shimada, Yasuhiro
Nakamura, Kenichi
Sato, Akihiro
Moriya, Yoshihiro
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2009, 39 (06) : 406 - 409
[23] A Phase II/III randomized controlled trial comparing perioperative versus postoperative chemotherapy with mFOLFOX6 for lower rectal cancer with suspected lateral pelvic node metastasis: Japan Clinical Oncology Group Study JCOG1310 (PRECIOUS study)
Ohue, Masayuki
Iwasa, Satoru
Kanemitsu, Yukihide
Hamaguchi, Tetsuya
Shiozawa, Manabu
Ito, Masaaki
Yasui, Masayoshi
Katayama, Hiroshi
Mizusawa, Junki
Shimada, Yasuhiro
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2017, 47 (01) : 84 - 87
[24] Randomized Phase II Open-Label Study of mFOLFOX6 in Combination With Linifanib or Bevacizumab for Metastatic Colorectal Cancer
O'Neil, Bert H.
Cainap, Calin
Van Cutsem, Eric
Gorbunova, Vera
Karapetis, Christos S.
Berlin, Jordan
Goldberg, Richard M.
Qin, Qin
Qian, Jiang
Ricker, Justin L.
Fischer, JuDee
McKee, Mark D.
Carlson, Dawn M.
Kim, Tae Won
CLINICAL COLORECTAL CANCER, 2014, 13 (03) : 156 - 163
[25] Phase 2 randomized controlled trial of intravenous or intraperitoneal paclitaxel plus mFOLFOX6 vs. mFOLFOX6 as first-line treatment of advanced gastric cancer
Zhao, Shen
Su, Liyu
Chen, Yigui
Li, Xiaofeng
Lin, Peicheng
Chen, Wujin
Fang, Wenzheng
Zhu, Jinfeng
Li, Hui
Ren, Liping
Liu, Jie
Hong, Yanni
Lin, Shaowei
Fan, Nanfeng
Lin, Rongbo
FRONTIERS IN ONCOLOGY, 2022, 12
[26] Vandetanib plus mFOLFOX6 in patients with advanced colorectal cancer (CRC): A randomized, double-blind, placebo-controlled phase II study
Yang, T. S.
Oh, D. Y.
Guimbaud, R.
Szanto, J.
Salek, T.
Thurzo, L.
Vieitez, J. M.
Pover, G. M.
Kim, T. W.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[27] Randomized phase III trial comparing preoperative versus postoperative radiotherapy with capecitabine in locally advanced rectal cancer
Park, J.
Ybon, S.
Choi, E.
Kim, Y.
Kim, J.
Yu, C.
Kim, T.
Chang, H.
Jang, S.
Kim, J.
EJC SUPPLEMENTS, 2009, 7 (02): : 330 - 330
[28] A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients
Van Cutsem, E.
Prenen, H.
D'Haens, G.
Bennouna, J.
Carrato, A.
Ducreux, M.
Bouche, O.
Sobrero, A.
Latini, L.
Staines, H.
Oum'Hamed, Z.
Dressler, H.
Studeny, M.
Capdevila, J.
ANNALS OF ONCOLOGY, 2015, 26 (10) : 2085 - 2091
[29] A randomized phase II trial comparing preoperative plus perioperative chemotherapy with preoperative chemotherapy in patients with locally advanced breast cancer
Rocca, Andrea
Peruzzotti, Giulia
Ghisini, Raffaella
Viale, Giuseppe
Veronesi, Paolo
Luini, Alberto
Intra, Mattia
Pietri, Elisabetta
Curigliano, Giuseppe
Giovanardi, Filippo
Maisonneuve, Patrick
Goldhirsch, Aron
Colleoni, Marco
ANTI-CANCER DRUGS, 2006, 17 (10) : 1201 - 1209
[30] Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial
Garcia-Aguilar, Julio
Chow, Oliver S.
Smith, David D.
Marcet, Jorge E.
Cataldo, Peter A.
Varma, Madhulika G.
Kumar, Anjali S.
Oommen, Samuel
Coutsoftides, Theodore
Hunt, Steven R.
Stamos, Michael J.
Ternent, Charles A.
Herzig, Daniel O.
Fichera, Alessandro
Polite, Blase N.
Dietz, David W.
Patil, Sujata
Avila, Karin
LANCET ONCOLOGY, 2015, 16 (08): : 957 - 966

← 1 2 3 4 5 →